Global metabolomic profiling of tumor tissue and paired serum samples to identify biomarkers for response to neoadjuvant FOLFIRINOX treatment of human pancreatic cancer
Neoadjuvant chemotherapy (NAT) is increasingly used for the treatment of non‐metastatic pancreatic ductal adenocarcinoma (PDAC) and is established as a standard of care for borderline resectable and locally advanced PDAC. However, full exploitation of its clinical benefits is limited by the lack of...
Saved in:
Main Authors: | Manoj Amrutkar, Sander Johannes Thorbjørnsen Guttorm, Anette Vefferstad Finstadsveen, Knut Jørgen Labori, Lars Eide, Helge Rootwelt, Katja Benedikte Prestø Elgstøen, Ivar P. Gladhaug, Caroline S. Verbeke |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2025-02-01
|
Series: | Molecular Oncology |
Subjects: | |
Online Access: | https://doi.org/10.1002/1878-0261.13759 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
改良FOLFIRINOX方案一线治疗晚期转移性胰腺癌
by: 农天文, et al.
Published: (2018-01-01) -
Total neoadjuvant chemotherapy according to the FOLFIRINOX regimen for locally advanced adenocarcinoma of the stomach and cardioesophageal junction: interim results
by: M. V. Sedova, et al.
Published: (2023-09-01) -
Metastatic pancreatic cancer now in remission: a case report and literature review
by: Charles W. Shi, et al.
Published: (2025-01-01) -
Surgical Treatment of Sporadic Pancreatic Neuroendocrine Tumors: A State of the Art Review
by: Sven-Petter Haugvik, et al.
Published: (2012-01-01) -
Survival benefits of adjuvant chemotherapy after conversion surgery in patients with advanced pancreatic cancer
by: Yoon Suk Lee, et al.
Published: (2025-01-01)